Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

NCT00219219 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Zoledronic acid

Sponsor

Novartis

Collaborators

[object Object]